Loading...

Takeda Pharmaceutical Company Limited

TAKNYSE
Healthcare
Drug Manufacturers - Specialty & Generic
$15.10
$0.04(0.27%)

Takeda Pharmaceutical Company Limited (TAK) Stock Overview

Explore Takeda Pharmaceutical Company Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 69.9/100

Key Financials

Market Cap47.5B
P/E Ratio23.74
EPS (TTM)$0.23
ROE0.04%

AI Price Forecasts

1 Week$15.51
1 Month$14.85
3 Months$14.28
1 Year Target$12.65

TAK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Takeda Pharmaceutical Company Limited (TAK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $12.65.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 23.74 and a market capitalization of 47.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for TAKStats details for TAK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations

Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$0.00
Average$0.00
High$0.00

Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

CEO

Mr. Christophe Weber

Employees

49,281

Headquarters

1-1, Nihonbashi-Honcho 2-chome, Tokyo

Founded

2010

Frequently Asked Questions

;